[CAS NO. 922050-57-5] HS56
PRODUCTS SPECIFICATIONS [922050-57-5]
DESCRIPTION [922050-57-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 317.75 |
| Molecular Formula | C13H8ClN5OS |
| SMILES | N#CCSC1=NC(N(C2=CC=CC(Cl)=C2)N=C3)=C3C(N1)=O |
Summary
HS56 is an ATP-competitive dual Pim/DAPK3 inhibitor with K i values of 0.26, 0.208, 2.94, and ＞100 μM for DAPK3, Pim-3, Pim-1, and Pim-2, respectively. HS56 inhibits LC20 phosphorylation and smooth muscle contraction. HS56 decreases blood pressure in spontaneously hypertensive mice. HS56 can be used in research of hypertension [1] .
IC50 & Target
|
PIM3 0.208 μM (Ki) |
PIM1 2.94 μM (Ki) |
PIM2 ＞100 μM (Ki) |
In Vitro
HS56 (50 μM; 16 h) delays force onset, decreases contractile force, and reduces LC20 phosphorylation in excised rat caudal arterial VSM tissues [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
| Cell Line: | VSM tissues |
| Concentration: | 50 μM |
| Incubation Time: | 16 hours |
| Result: | Modulated LC20 phosphorylation in VSM tissues. |
In Vivo
HS56 (10 and 20 mg/kg; i.v.; single injection) decreases blood pressure (BP) in spontaneously hypertensive mice [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Spontaneously hypertensive renin transgene and wild-type (WT) mice [1] |
| Dosage: | 10 and 20 mg/kg |
| Administration: | Intravenous injection, single injection |
| Result: | Induced dose-dependent decreases in systolic blood pressure. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.